Product image of Mestinon (Pyridostigmine Bromide) supplied by GNH India

Mestinon

Active Ingredient:
Pyridostigmine Bromide
Origin:
EU

Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for systemic use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis, to stimulate bowel motility after surgery, and to reverse the effects of non‑depolarizing neuromuscular blocking agents.

GNH India supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies globally, and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics.

Manufacturer / TM Owner

Viatris Austria Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mestinon (pyridostigmine bromide) acts as an acetylcholinesterase inhibitor to enhance neuromuscular transmission in several clinical settings.

  • Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction.
  • Postoperative ileus: stimulates gastrointestinal motility to reduce postoperative bowel paralysis.
  • Reversal of non‑depolarizing neuromuscular blockade: counteracts residual blockade after anesthesia, facilitating recovery of muscle function.

How It Works

  • Pyridostigmine bromide reversibly binds to the active site of acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in synaptic clefts. By competitively inhibiting this enzyme, the drug prolongs acetylcholine availability at nicotinic receptors of the neuromuscular junction, thereby enhancing cholinergic transmission and improving muscle contraction. The inhibition is temporary, allowing normal enzyme activity to resume after the drug is cleared.

Side Effects

Adverse reactions to pyridostigmine bromide vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools often occurring shortly after dosing.
  • Abdominal cramps: intermittent stomach discomfort.
  • Increased salivation: excess oral secretions.
  • Muscle cramps: involuntary tightening of skeletal muscles.
  • Sweating: excessive perspiration.

Serious or Rare Side Effects

  • Bronchospasm: constriction of airway muscles, especially in asthmatic patients.
  • Severe bradycardia: markedly slow heart rate that may require medical attention.
  • Cholinergic crisis: excessive cholinergic activity leading to muscle weakness and respiratory compromise.
  • Seizures: rare central nervous system events.
  • Allergic reactions: rash, itching, or anaphylaxis in susceptible individuals.

Precautions & Warnings

When prescribing pyridostigmine bromide, clinicians should consider several safety measures.

  • Monitor for cholinergic excess: watch for muscle twitching, sweating, bradycardia.
  • Adjust dose in renal impairment: reduced clearance may increase drug exposure.
  • Caution in asthma or COPD: risk of bronchospasm.
  • Avoid concurrent anticholinergic agents: may diminish therapeutic effect.
  • Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
  • Store at ambient temperature: keep in original container, protect from moisture.

Avoid Interactions

Pyridostigmine bromide can interact with several medication classes.

Major Interactions (Avoid)

  • Beta‑blockers: may exacerbate bradycardia.
  • Succinylcholine: enhanced cholinergic effects leading to prolonged paralysis.
  • Other cholinesterase inhibitors: risk of cholinergic crisis.

Moderate Interactions (Monitor Closely)

  • Anticholinergic drugs (e.g., atropine): may reduce efficacy.
  • Diuretics that cause hypokalemia: can increase risk of muscle weakness.

Frequently Asked Questions

Mestinon (pyridostigmine bromide) is prescribed for myasthenia gravis to improve muscle strength, for postoperative ileus to stimulate bowel motility, and to reverse the effects of non‑depolarizing neuromuscular blocking agents after surgery.

Pyridostigmine competitively inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. By slowing this breakdown, more acetylcholine remains at neuromuscular junctions, enhancing nerve‑muscle communication and improving muscle contraction.

The exact dose of Mestinon is determined by the prescribing clinician based on the patient’s condition, severity, renal function and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for pyridostigmine in pregnancy and lactation are limited. It is classified as pregnancy category unknown, so it should only be used when the potential benefit justifies any possible risk to the fetus or infant.

To request Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon belongs to the acetylcholinesterase inhibitor class, which directly increases acetylcholine at the neuromuscular junction. Other muscle relaxants, such as benzodiazepines, act centrally on the CNS. Pyridostigmine’s mechanism makes it particularly effective for disorders like myasthenia gravis where peripheral neuromuscular transmission is impaired.

Mestinon tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mestinon is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency depend on the individual treatment plan and should be followed exactly as prescribed.

Serious risks include cholinergic crisis, severe bradycardia, bronchospasm, seizures and allergic reactions such as anaphylaxis. Patients should be monitored for signs of excessive cholinergic activity and seek immediate medical attention if severe symptoms develop.

Mestinon should be avoided in patients with known hypersensitivity to pyridostigmine or any component of the formulation, in those with uncontrolled asthma or severe COPD, and in individuals where the risk of cholinergic excess outweighs potential benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pyridostigmine Bromide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT